Amandine Even
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amandine Even has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Louis-Eric Trudeau
Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
16 shared publications Sriparna Mukherjee
9 shared publications- Alex Tchung
Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Canada; Department of Neurosciences, Faculty of Medicine, Université de Montréal, Canada; Neural Signaling and Circuitry Research Group (SNC), Canada; Center for Interdisciplinary Research on the Brain and Learning (CIRCA), Canada; Institut Courtois d'Innovation Biomédicale (CI2B), Montréal, QC H3C 3J7, Canada
3 shared publications - Nicolas Giguère
Department of pharmacology and physiology, Faculty of Medicine, Université de Montréal, Québec, Canada
3 shared publications - Sriparna Mukherjee
Department of pharmacology and physiology, Faculty of Medicine, Université de Montréal, Québec, Canada
3 shared publications - Claudie Beaulieu
Department of neurosciences, Faculty of Medicine, Université de Montréal, Québec, Canada
2 shared publications
Latest Publications
- Open Access
Repeated exposure to viral and bacterial danger signals in Parkin deficient mice induces inflammation but fails to trigger parkinsonism
Experimental models of Parkinson’s disease (PD) traditionally involve direct perturbations of the functioning of dopamine (DA) neurons. However, PD is increasingly recognized as multifactorial in origin and involving both cell-autonomous vulnerability factors and non-cell-autonomous triggers including inflammatory signals deriving from bacterial or viral infections. Notably, genes associated with early-onset familial PD as PRKN (Parkin) and PINK1 , are ubiquitously expressed and have been implicated in immune regulation, further supporting a role for inflammation in disease etiology. In the present study, we tested the hypothesis that alternate Polyinosinic:polycytidylic acid (Poly(I:C)), mimicking viral infection, and lipopolysaccharides (LPS), mimicking bacterial infection, may induce sufficient brain inflammation to impair the DA system in Parkin-deficient mice and recapitulate some of the systemic features of PD. We developed a protocol with alternating Poly(I:C) and LPS, inducing acute peripheral inflammation in both genotypes, with consistent body weight loss and an increase of fecal lipocalin-2. Modest levels of neuroinflammation were present six months after the treatment, with higher levels of the microglial marker Iba1 in the dorsal striatum and reduced levels of the astrocyte marker GFAP in the mesencephalon, potentially indicating reduced neuronal support in the longer term. Finally, we find that this alternating Poly(I:C)/LPS treatment does not induce dopaminergic denervation or motor dysfunctions, even in Parkin KO mice. Taken together, our findings suggest that repeated short-term exposure to pathogen-derived signals is insufficient to induce DA system impairment in young adult Parkin deficient mice. Instead, induction of PD-like pathology may require a convergence of factors, including a prolonged or recurrent inflammatory burden, aging, genetic susceptibility, and potentially additional environmental or cellular stressors, that together create a pathogenic “perfect storm”. Thus, in its current form, the paradigm developed in the present study should not be regarded as a fully representative model of PD. Rather, it provides proof of concept that temporally alternating inflammatory stimuli can shape non-motor symptom-like phenotypes and underscores the need for future animal model research to incorporate interacting risk factors, disease duration, and age-dependent vulnerability.
Open AccessRepeated exposure to viral and bacterial danger signals in Parkin deficient mice induces inflammation but fails to trigger parkinsonism
Experimental models of Parkinson’s disease (PD) traditionally involve direct perturbations of the functioning of dopamine (DA) neurons. However, PD is increasingly recognized as multifactorial in origin and involving both cell-autonomous vulnerability factors and non-cell-autonomous triggers including inflammatory signals deriving from bacterial or viral infections. Notably, genes associated with early-onset familial PD as PRKN (Parkin) and PINK1 , are ubiquitously expressed and have been implicated in immune regulation, further supporting a role for inflammation in disease etiology. In the present study, we tested the hypothesis that alternate Polyinosinic:polycytidylic acid (Poly(I:C)), mimicking viral infection, and lipopolysaccharides (LPS), mimicking bacterial infection, may induce sufficient brain inflammation to impair the DA system in Parkin-deficient mice and recapitulate some of the systemic features of PD. We developed a protocol with alternating Poly(I:C) and LPS, inducing acute peripheral inflammation in both genotypes, with consistent body weight loss and an increase of fecal lipocalin-2. Modest levels of neuroinflammation were present six months after the treatment, with higher levels of the microglial marker Iba1 in the dorsal striatum and reduced levels of the astrocyte marker GFAP in the mesencephalon, potentially indicating reduced neuronal support in the longer term. Finally, we find that this alternating Poly(I:C)/LPS treatment does not induce dopaminergic denervation or motor dysfunctions, even in Parkin KO mice. Taken together, our findings suggest that repeated short-term exposure to pathogen-derived signals is insufficient to induce DA system impairment in young adult Parkin deficient mice. Instead, induction of PD-like pathology may require a convergence of factors, including a prolonged or recurrent inflammatory burden, aging, genetic susceptibility, and potentially additional environmental or cellular stressors, that together create a pathogenic “perfect storm”. Thus, in its current form, the paradigm developed in the present study should not be regarded as a fully representative model of PD. Rather, it provides proof of concept that temporally alternating inflammatory stimuli can shape non-motor symptom-like phenotypes and underscores the need for future animal model research to incorporate interacting risk factors, disease duration, and age-dependent vulnerability.
- Open Access
- 21 April 2026
- Published by Springer Nature
Spleen collection from mice and determination of spleen index v1
This protocol describes the collection of spleen from mice and the calculation of the spleen index.
- 21 April 2026
- Published by Springer Nature
Open AccessSpleen collection from mice and determination of spleen index v1
This protocol describes the collection of spleen from mice and the calculation of the spleen index.
- Open Access
- 21 April 2026
- Published by Springer Nature
Collection and preparation of colon from mice to calculate the colon index and for immunohistochemistry v1
This protocol describes the collection of colon from mice, the calculation of the index and the preparation for futur RNA, protein, immunohistopathology or immunohistochemistry analysis.
- 21 April 2026
- Published by Springer Nature
Open AccessCollection and preparation of colon from mice to calculate the colon index and for immunohistochemistry v1
This protocol describes the collection of colon from mice, the calculation of the index and the preparation for futur RNA, protein, immunohistopathology or immunohistochemistry analysis.
- Open Access
- 21 April 2026
- Published by Springer Nature
Automated counting of microglia in mouse brain slices after immunofluorescence staining v1
Standardized procedure for automated detection and counting of microglia in floating brain sections using AI-based segmentation.
- 21 April 2026
- Published by Springer Nature
Open AccessAutomated counting of microglia in mouse brain slices after immunofluorescence staining v1
Standardized procedure for automated detection and counting of microglia in floating brain sections using AI-based segmentation.
- Open Access
- 20 April 2026
- Published by Springer Nature
Western Blot v1
This protocol describes SDS-PAGE, transfer to nitrocellulose, immunoblotting, chemiluminescent imaging, stripping, reprobing, and densitometric analysis.
- 20 April 2026
- Published by Springer Nature
Open AccessWestern Blot v1
This protocol describes SDS-PAGE, transfer to nitrocellulose, immunoblotting, chemiluminescent imaging, stripping, reprobing, and densitometric analysis.
- Open Access
- 20 April 2026
- Published by Springer Nature
Protein extraction and quantification from mouse tissues or cells v1
This protocol describes protein extraction and quantification from tissue (with RIPA buffer and BCA assay) or cells (with Laemmli buffer and EZQ kit) .
- 20 April 2026
- Published by Springer Nature
Open AccessProtein extraction and quantification from mouse tissues or cells v1
This protocol describes protein extraction and quantification from tissue (with RIPA buffer and BCA assay) or cells (with Laemmli buffer and EZQ kit) .
- Open Access
- 20 April 2026
- Published by Springer Nature
Immune cell isolation from mouse brain and spleen for flow cytometry v1
This protocol outlines the procedures for terminal in vivo CD45 labeling, enzymatic dissociation of mouse brain tissue using collagenase D and DNase I, myelin removal via a Percoll gradient, and mechanical preparation of single-cell suspensions from the spleen. It also includes steps for red blood cell lysis in spleen lysate, antibody staining, fixation, and subsequent flow cytometric analysis of immune cells isolated from both brain and spleen tissues.
- 20 April 2026
- Published by Springer Nature
Open AccessImmune cell isolation from mouse brain and spleen for flow cytometry v1
This protocol outlines the procedures for terminal in vivo CD45 labeling, enzymatic dissociation of mouse brain tissue using collagenase D and DNase I, myelin removal via a Percoll gradient, and mechanical preparation of single-cell suspensions from the spleen. It also includes steps for red blood cell lysis in spleen lysate, antibody staining, fixation, and subsequent flow cytometric analysis of immune cells isolated from both brain and spleen tissues.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Utilisation de la thérapie cellulaire à l'aide de cellules dendritiques tolérogènes autologues en transplantation et dans les pathologies inflammatoires
Diverses études, dont celles menées par l’équipe de MC CUTURI, ont montré l’efficacité de la thérapie cellulaire à l’aide de cellules dendritiques tolérogènes dans le contrôle du rejet de greffe chez le rongeur. L’originalité de nos travaux réside dans l’utilisation de cellules autologues, les ATDC (Autologous Tolerogenic Dendritic Cells). Dans l’optique de leur application clinique en transplantation rénale, les ATDC ont été générées chez des volontaires sains. Le premier objectif de ma thèse a été de valider le procédé de fabrication de grade clinique des ATDC humaines. De plus, ces travaux ont montré que les ATDC générées à partir de monocytes de patients atteints d’insuffisance rénale présentent les mêmes propriétés tolérogènes in vitro que celles issues de volontaires sains. Enfin, les ATDC humaines, à l’instar de leurs analogues murines, sont capables de réaliser une présentation croisée d’antigène. Le second objectif a été d’étudier le rôle du récepteur à la fractalkine, le CX3CR1, fortement exprimé par nos cellules. Mes résultats indiquent que l’absence de CX3CR1 ne modifie pas la génération des ATDC murines, ni leur survie, ou leur capacité de régulation des LT in vitro. Le troisième objectif de cette thèse a été d’élargir l’utilisation des ATDC murines à d’autres pathologies inflammatoires. Bien qu’elles ne semblent pas inhiber le développement de la colite, les ATDC protègent les souris de l’induction de l’asthme allergique. Ces résultats ont permis à l’équipe de réaliser le premier essai clinique de thérapie cellulaire à l’aide de TolDC en transplantation rénale. Cet essai de phase I/II permettra d’étudier l'innocuité et l'efficacité des ATDC puis potentiellement d’étendre l'utilisation clinique des ATDC, notamment chez des patients asthmatiques.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Utilisation de la thérapie cellulaire à l'aide de cellules dendritiques tolérogènes autologues en transplantation et dans les pathologies inflammatoires
Diverses études, dont celles menées par l’équipe de MC CUTURI, ont montré l’efficacité de la thérapie cellulaire à l’aide de cellules dendritiques tolérogènes dans le contrôle du rejet de greffe chez le rongeur. L’originalité de nos travaux réside dans l’utilisation de cellules autologues, les ATDC (Autologous Tolerogenic Dendritic Cells). Dans l’optique de leur application clinique en transplantation rénale, les ATDC ont été générées chez des volontaires sains. Le premier objectif de ma thèse a été de valider le procédé de fabrication de grade clinique des ATDC humaines. De plus, ces travaux ont montré que les ATDC générées à partir de monocytes de patients atteints d’insuffisance rénale présentent les mêmes propriétés tolérogènes in vitro que celles issues de volontaires sains. Enfin, les ATDC humaines, à l’instar de leurs analogues murines, sont capables de réaliser une présentation croisée d’antigène. Le second objectif a été d’étudier le rôle du récepteur à la fractalkine, le CX3CR1, fortement exprimé par nos cellules. Mes résultats indiquent que l’absence de CX3CR1 ne modifie pas la génération des ATDC murines, ni leur survie, ou leur capacité de régulation des LT in vitro. Le troisième objectif de cette thèse a été d’élargir l’utilisation des ATDC murines à d’autres pathologies inflammatoires. Bien qu’elles ne semblent pas inhiber le développement de la colite, les ATDC protègent les souris de l’induction de l’asthme allergique. Ces résultats ont permis à l’équipe de réaliser le premier essai clinique de thérapie cellulaire à l’aide de TolDC en transplantation rénale. Cet essai de phase I/II permettra d’étudier l'innocuité et l'efficacité des ATDC puis potentiellement d’étendre l'utilisation clinique des ATDC, notamment chez des patients asthmatiques.
- Open Access
- 31 March 2026
- Published by Springer Nature
Intraperitoneal LPS or Poly(I:C) injection and monitoring of mice v1
This protocol describes the induction of systemic inflammation in mice using intraperitoneal injections of LPS or Poly(I:C). It includes drug preparation, injection procedures, post-injection monitoring (sepsis scoring and body weight) over several days. This approach is used to model bacterial-like and viral-like immune responses in vivo.
- 31 March 2026
- Published by Springer Nature
Open AccessIntraperitoneal LPS or Poly(I:C) injection and monitoring of mice v1
This protocol describes the induction of systemic inflammation in mice using intraperitoneal injections of LPS or Poly(I:C). It includes drug preparation, injection procedures, post-injection monitoring (sepsis scoring and body weight) over several days. This approach is used to model bacterial-like and viral-like immune responses in vivo.
- Open Access
- 31 March 2026
- Published by Springer Nature
Blood collection and serum preparation in mice v1
This protocol describes blood collection from mice and serum preparation. The resulting serum can be used for ELISA or multiplex cytokine assays.
- 31 March 2026
- Published by Springer Nature
Open AccessBlood collection and serum preparation in mice v1
This protocol describes blood collection from mice and serum preparation. The resulting serum can be used for ELISA or multiplex cytokine assays.